Shinzaburo Noguchi

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina et al. · The Lancet · 2016 · 580 citations · Full text

Mg Versus, Breast Oncology, Oncology +8

Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

Tomonori Tanei, Koji Morimoto, Kenzo Shimazu et al. · Clinical Cancer Research · 2009 · 560 citations

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Martine Piccart, Gabriel N. Hortobágyi, Mario Campone et al. · Annals of Oncology · 2014 · 554 citations · Full text

Breast Oncology, Oncology, Medicine +6

Induction of <i>WT1</i> (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

Akihiro Tsuboi, Tetsuya Taguchi, Tadashi Osaki et al. · Proceedings of the National Academy of Sciences · 2004 · 524 citations · Full text

Cytotoxic T Lymphocytes, Wt1 Peptide, Immune Regulation +24